Breaking News

Tweet TWEET

Replicel and Shiseido Announce Collaboration and Technology Transfer Framework Agreement and Exclusive Geographic Technology

Replicel and Shiseido Announce Collaboration and Technology Transfer Framework 
Agreement and Exclusive Geographic Technology License 
TOKYO, JAPAN and VANCOUVER, BRITISH COLUMBIA -- (Marketwired) --
05/29/13 -- RepliCel Life Sciences Inc. (the "Company" or "RepliCel")
(OTCBB:REPCF)(CNSX:RP) and Shiseido Company, Limited ("Shiseido")
(TSE:4911)(PINKSHEETS:SSDOY) announced today that they have entered
into a Collaboration and Technology Development Transfer Framework
Agreement ("the Agreement") for an exclusive geographic license for
RepliCel's RCH-01 hair regeneration technology. Under the final
agreement, Shiseido will pay RepliCel an upfront fee of yen
400,000,000. In addition, Shiseido will pay RepliCel sales milestones
up to yen 3,000,000,000. Replicel is also entitled to royalties on
sales. 
David Hall, CEO and President of RepliCel states, "Shiseido is one of
the oldest and most respected cosmetics companies in the world with
annual sales in excess of US$6.7 billion. Since its inception in
1872, they have stood at the forefront of science, innovation and
beauty. They are known throughout the industry for their research and
development in skin and hair biology as well as expertise in
formulation and manufacturing. This Agreement for our RCH-01
autologous cell therapy for pattern baldness is consistent with our
goal to partner with the leading companies in the field of hair
regeneration. The Agreement also represents a key validation of our
technology platform being built around the concept of addressing
cellular deficits in human conditions." 
"Shiseido's corporate mission is a research driven focus on human
beauty and wellness," stated Mr. Youchi Shimatani, Shiseido's
corporate officer in charge of research and development. "Our hair
cell related research is to support those people suffering with
pattern baldness. With this focus, I am delighted to be entering into
a technical partnership with RepliCel which is a leader in hair
regenerative technology," concluded Mr. Shimatani. 
Professor Rolf Hoffmann, RepliCel's Chief Medical Officer commented,
"The Agreement will ultimately see further human clinical trials
being conducted by Shiseido in its territory. In addition, the
Agreement anticipates ongoing research collaboration for the
continued improvement of the technology. As Shiseido has world-class
technical expertise in hair biology, we anticipate that together we
will develop further improvements to the technology. As a co-founder
of the Company, I am extremely pleased to be partnering with a leader
in hair science." 
RCH-01 is a patented hair follicle cell replication and implantation
technology designed to rejuvenate damaged, miniaturized hair
follicles in balding scalp skin. This technology has been developed
over ten years of research, experimentation and trials. The mechanics
of this technology involve the extraction of as few as 20 hair
follicles from the back of a patient's scalp where healthy cycling
hair follicles reside. Specific cells are isolated from the hair
follicles and are then replicated in a current Good Manufacturing
Practice compliant facility through the Company's proprietary
cellular replication process, and are then reintroduced back into
balding areas on a patient's scalp. The implanted cells are expected
to rejuvenate damaged hair follicles leading to the growth of new
healthy hair fibers.  
"The Shiseido agreement represents another significant step in the
development of RCH-01", stated Dr. Kevin McElwee, Chief Scientific
Officer. "We are excited to be collaborating with such a skilled
group of scientists."  
The Agreement encompasses a geographic area including Japan, China,
South Korea, Taiwan and the ASEAN countries representing a population
of approximately 2.1 Billion people. Joint steering committees will
be established to oversee the transfer of the technology, knowhow and
standard operating procedures. 
About RepliCel Life Sciences  
The Company is developing two autologous cell therapies. The first is
a cellular treatment for androgenetic alopecia (pattern baldness)
named RepliCel Hair-01 (RCH-01). The second is a cell therapy for the
treatment of chronic tendon injuries named RepliCel Tendon-01
(RCT-01). Both treatments are based on RepliCel's innovative
technology which utilizes cells isolated from a patient's own healthy
hair follicles to address specific cellular deficits. Phase II
clinical trials, for both technologies, are planned for the later
part of 2013. 
About Shiseido Company, Limited  
Shiseido started business in Ginza, Tokyo in 1872 as the first
Western-style pharmacy in Japan. Since then, the company has led the
cosmetic technology and culture in Japan over more than 100 years.
The company now aspires to become a "global player to represent Asia
with origins in Japan" and operate businesses all over the world,
including Europe, the U.S. and Asia. Its representative global brand,
"SHISEIDO" is now sold in 89 countries and regions as of April 2013.  
Notice Regarding Forward Looking Statements 
This press release contains projections and forward-looking
statements, as that term is defined under applicable securities laws.
Statements in this press release, which are not purely historical,
are forward-looking statements and include the following: (i) that
the Company and Shiseido will enter into a definitive license
agreement for an exclusive geographic license for RepliCel's RCH-01
hair regeneration technology and receive the payments set out above;
(2) that the Company will partner with the leading companies in the
field of hair regeneration, including Shiseido; (3) that the Company
will ultimately see further human clinical trials being conducted;
(4) that ongoing research collaboration will be conducted by the
Company and Shiseido for the continued improvement of the technology;
(5) that the Company and Shiseido will develop further improvements
to the technology; (6) that the Company's technology will rejuvenate
damaged hair follicles leading to the growth of new healthy hair
fibers; and (7) Phase II clinical trials, for both the hair
technology and the tendon technology, will be conducted in the later
part of 2013. These statements are only predictions and involve known
and unknown risks which may cause actual results and the Company's
plans and objectives to differ materially from those expressed in the
forward-looking information, including: that the Company and Shiseido
may not be able to negotiate and enter into a definitive license
agreement pursuant to which the Company will license to Shiseido an
exclusive geographic license for RepliCel's RCH-01 hair regeneration
technology; that the Company and Shiseido may not be able to agree on
the research and development to be conducted in connection with the
Company's technology; that negative results from the Company's
clinical trials may impact further trials and development of the
technology; the effects of government regulation on the Company's
business, including the future development of the technology; risks
associated with the Company's ability to obtain and protect rights to
its intellectual property; risks and uncertainties associated with
the Company's ability to raise additional capital; and other factors
beyond the Company's control. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity or
performance.  
Further, any forward-looking statement speaks only as of the date on
which such statement is made, and, except as required by applicable
law, the Company undertakes no obligation to update any
forward-looking statement to reflect events or circumstances after
the date on which such statement is made or to reflect the occurrence
of unanticipated events. New factors emerge from time to time, and it
is not possible for management to predict all of such factors and to
assess in advance the impact of such factors on the Company's
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statement. Readers should consult
all of the information set forth herein and should also refer to the
risk factor disclosure outlined in the Company's annual report on
Form 20-F for the fiscal year ended December 31, 2012 and other
periodic reports filed from time-to-time with the Securities and
Exchange Commission on Edgar at www.sec.gov and with the British
Columbia Securities Commission on Sedar at www.sedar.com.
Contacts:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
tg@replicel.com
www.replicel.com
Contacts:
Shiseido Company, Limited
Tatsuyoshi Endo
Public Relations Department
+81-3-6218-5200
tatsuyoshi.endo@to.shiseido.co.jp
www.shiseido.com